Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

CDK4/6 inhibitors with endocrine therapy as neoadjuvant treatment, with ctDNA-guided therapy after surgery

Phase 2 trial of neoadjuvant CDK4/6 inhibitor plus endocrine therapy. The registry says post-surgery treatment is guided by ctDNA status, and the primary outcome is the ctDNA clearance rate after neoadjuvant therapy. ClinicalTrials.gov lists the study as recruiting.

Peking University People's Hospital